The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...
Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...
Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...
ASCO recommends osimertinib consolidation for patients with unresectable, stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation who have completed chemoradiation.
AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung ...
September 26, 2024--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth ...
Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years AstraZeneca’s TAGRISSO®(osimertinib) has been approved in the ...
WILMINGTON, Del., September 26, 2024--AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback